Author Of 1 Presentation
P0493 - Severe infections in patients with multiple sclerosis: a nationwide registry study in Argentina (ID 929)
- E. Silva
- C. Vrech
- A. Pappolla
- J. Miguez
- L. Patrucco
- J. Correale
- M. Marrodan
- M. Gaitán
- M. Fiol
- L. Negrotto
- C. Ysrraelit
- E. Cristiano
- A. Carrá
- A. Chertcoff
- J. Steinberg
- A. Martinez
- C. Curbelo
- L. Cohen
- R. Alonso
- O. Garcea
- C. Pita
- B. Silva
- G. Luetic
- N. Deri
- M. Balbuena
- V. Tkachuk
- E. Carnero Contentti
- P. Lopez
- J. Pettinicchi
- A. Caride
- M. Burgos
- F. Leguizamon
- E. Knorre
- R. Piedrabuena
- A. Barboza
- S. Liwacki
- P. Nofal
- G. Volman
- A. Alvez Pinheiro
- J. Hryb
- D. Tavolini
- P. Blaya
- L. Recchia
- C. Mainella
- M. Kohler
- E. Kohler
- J. Blanche
- S. Tizio
- M. Saladino
- F. Caceres
- N. Fernandez Liguori
- L. Lazaro
- G. Zanga
- M. Parada Marcilla
- M. Fracaro
- F. Pagani Cassará
- G. Vazquez
- V. Sinay
- G. Sgrilli
- P. Divi
- M. Jacobo
- E. Reich
- L. Cabrera
- M. Menichini
- M. Coppola
- I. Martos
- J. Viglione
- G. Jose
- S. Bestoso
- R. Manzi
- D. Giunta
- M. Doldan
- M. Alonso Serena
- J. Rojas
Abstract
Background
Data on the rates of infections among patients with multiple sclerosis (MS) are sparse and even more from Latin American countries.
Objectives
The objective of this study was to quantify the incidence of severe infections (SI) in patients with MS included in the Argentinean MS and NMOSD registry (RelevarEM, NCT 03375177).
Methods
RelevarEM is a longitudinal, strictly observational MS and NMOSD registry in Argentina. From May 2018 to March 2020, the centers and principal investigators were contacted and incorporated into the Registry. SI were defined as those that required intravenous treatment or that led to hospitalization or death. Patients contributed person-years of follow-up for the study period. Incidence rates and 95% CI were calculated.
Results
A total of 2158 patients with MS were included, mean age 42 (IIQ 34-52), 65,5% (1576) were female, 82,3% were RRMS. During the period (May 2018-March 2020), 28 SI were reported (IR 1.16, 95%CI 0.77-1.68). In patients with SI, the mean age was 54 (min 43- max 63, p<0.01) years, 11 (39%) were secondary progressive MS (p<0.01), the mean EDSS was 6.5 (range 5-8)(p<0.01), mean disease duration 12 years (p<0.01). 42% of patients were free of MS treatment while 17% were on injectables, 25% on orals and 10% on monoclonal antibodies (p=0.24). The most common sites of severe infection were the lower respiratory tract (39%)
Conclusions
IR of severe infection during the study period was 1.16 (95%CI 0.77-1.68). Most frequent SI were in SPMS and older patients while no relation was observed regarding MS treatment.